Myeloma Treatment: Then and Now

Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!
BY Brielle Benyon
PUBLISHED December 09, 2018

Back in 2008, Velcade (bortezomib) was just being approved to treat patients with multiple myeloma. A combination called RVd – Revlimid (lenalidomide), Velcade and dexamethasone – eventually became standard of care for this patient population after it showed promising results in the SWOG S077 trial.

However, not everyone can tolerate this combination, so a new option, “RVd lite,” is being explored.

Since, 2018 has also had some major Food and Drug Administration (FDA) moves, pushing the field far beyond where it was a decade ago.
The year has been an exciting one for the treatment of myeloma, and there is sure to be even more advances made in 2019. To read more and stay up to date with all myeloma news, visit
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Myeloma CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In